2024 ASH Featured Research

The 66th American Society of Hematology (ASH) Annual Meeting and Exposition showcases research from authors affiliated with the University of Illinois Cancer Center, the University of Illinois Chicago (UIC) and UI Health, UIC’s academic health enterprise.

Below is a list of their featured work. ASH will be held December 7–10 in San Diego, California.


Haploidentical Peripheral Blood Stem Cell Transplantation in 20 Adult Patients with Sickle Cell Disease

Ekaterina Proskuriakova, MD1, Elisa Zucchetti, MD2, Karen Sweiss, PharmD3, Nadim Mahmud, MBBS, PhD4, Matthew Koshy, MD5, Damiano Rondelli, MD6 and Santosh L. Saraf, MD7

1Mount Sinai Hospital, Chicago, IL
2University of Illinois Chicago, Chicago
3Department of Pharmacy Practice, University of Illinois Chicago, Hinsdale, IL
4Section of Hematology/Oncology, Department of Medicine, Univ. of Illinois Chicago, Chicago, IL
5Department of Radiation Oncology, University of Illinois Chicago, Chicago, IL
6Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
7Department of Medicine, University of Illinois College of Medicine, Willowbrook, IL


Understanding the Menopause Transition in Sickle Cell Disease: An Interim Analysis of the Implementation of the Adapted Menopause Transition Questionnaire

Marwah Farooqui, DO1, Insia Rizvi, MBBS2, Lewis L Hsu, MD, PhD3, Santosh L. Saraf, MD1, Jin Han, PharmD4, Taif Hassan5, Robert Molokie, MD6, Franklin Njoku, MD1 and Gelila Goba, MD, MPH7

1Division of Hematology/Oncology, University of Illinois Chicago, Chicago, IL
2Division of Hematology and Oncology, University of Illinois Chicago, Chicago, IL
3Sickle Cell Center / Pediatric Hematology-Oncology, University of Illinois Chicago, Chicago, IL
4College of Pharmacy, University of Illinois Chicago, Chicago, IL
5University of Illinois Chicago, Chicago, IL
6Division of Hematology Oncology, University of Illinois, Chicago
7Department of Obstetrics & Gynecology, University of Illinois, Chicago


Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Karen Sweiss, PharmD1, Kyeongmin Kim, PhD Candidiate2, Yizhen Guo, PhD2, Kasey Hill, PhD2, Nicole Abbott, PhD2, Matias Eugenio Sanchez, MD3, Chukwuemeka Uzoka, MD3, Ana Maria Avila Rodriguez, MD3, John G Quigley4, Nadim Mahmud, MBBS, PhD5, Damiano Rondelli, MD6, Douglas W Sborov, MD7, Donald Harvey, PharmD8, Ajay K. Nooka, MD, MPH9, Madhav V. Dhodapkar, MD PhD10, Jonathan L. Kaufman, MD10, Nisha S. Joseph, MD10, Sagar Lonial, MD10, Pritesh Patel, MD3, Mitch A. Phelps, PhD2 and Craig C. Hofmeister, MD10

1Department of Pharmacy Practice, University of Illinois at Chicago, Hinsdale, IL
2The Ohio State University, Columbus, OH
3Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL
4Division of Hematology/Oncology, University of Illinois, Chicago, Chicago, IL
5Section of Hematology/Oncology, Department of Medicine, Univ. of Illinois Chicago, Chicago, IL
6Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
7Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
8Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
9Winship Cancer Institute of Emory University, Atlanta
10Winship Cancer Institute of Emory University, Atlanta, GA


Concurrent GBT1118 & Losartan Treatment Improves Sickle Cell Nephropathy

Guohui Ren, MD, PhD1, Maria Armila Ruiz, MS2, Suman Setty3, Victor R. Gordeuk, MD4 and Santosh L. Saraf, MD5

1University of Illinois At Chicago, CHICAGO, IL
2University of Illinois At Chicago, Chicago, IL
3University of Illinois Chicago, Chicago, IL
4Department of Medicine, University of Illinois Hospital, Chicago, IL
5Department of Medicine, University of Illinois College of Medicine, Willowbrook, IL


Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies

Francesca Cottini, MD1, Ana Maria Avila Rodriguez, MD2, Karen Sweiss, PharmD3, Chukwuemeka Uzoka, MD4, Zhengjia Chen, PhD5, Weiwei Ma, MS6, Elvira Umyarova, MD1, Anjali Satoskar7, Pierre Rodriguez, MD8 and Matias Sanchez, MD3

1Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
2Division of Hematology/Oncology, University of Illinois Chicago, Chicago, IL
3Division of Hematology/Oncology, University of Illinois Cancer Center, Chicago, IL
4Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
5Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois Chicago, Chicago, IL
6Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois, Chicago, IL
7Ohio State University, Columbus, OH
81950 W.Polk St.Chicago, IL, John Stroger,Jr.Hospital of Cook County, Chicago, IL


National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

Karen Sweiss, PharmD1, Jay R. Hydren, PhD2, Jorge Arturo Hurtado Martinez, MD2, Mason S. Barnes, B.S.2, Pritesh Patel, MD3, Douglas W Sborov, MD4, Jennifer M. Ahlstrom, BA2, Lisa Sharp, PhD, BSN, MA5 and Craig C. Hofmeister, MD6

1Department of Pharmacy Practice, University of Illinois Chicago, Hinsdale, IL
2HealthTree Foundation, Lehi, UT
3Division of Hematology/Oncology, University of Illinois Chicago, Chicago, IL
4Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
5University of Illinois Chicago, Chicago, IL
6Winship Cancer Institute of Emory University, Atlanta, GA


The Caprini Score in Black and Latino Patients: A Proposed Race- and Ethnicity-Adjusted Model for Perioperative Venous Thromboembolism Risk Assessment

Ahmad Nassar, MBBS1, Ryan Sun, MD2, Danny Hadidi3, Margaret E Wright4, Subhash K Kolar Rajanna5, Sargam Kapoor, MBBS6, Thomas L. Ortel, MD, PhD7 and John G Quigley8

1University of Illinois Chicago, Chicago, IL
2Division of Hematology and Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL, Chicago, IL
3Department of Internal Medicine, St. Luke’s Hospital, Chesterfield, MO
4University of Illinois Cancer Center, Chicago, IL
5Center for Clinical and Translational Science, University of Illinois Chicago, Chicago
6Division of Hematology, Department of Medicine, Duke University, Durham, NC
7Division of Hematology, Duke University School of Medicine, Durham, NC
8Division of Hematology/Oncology, University of Illinois, Chicago, Chicago, IL


Procalcitonin Levels Predict Bacterial Infections and Clinical Outcomes in Adults with Sickle Cell Disease

Rochelle Fayngor, MD1, Franklin Njoku, MD2, Insia Rizvi, MBBS3, Marwah Farooqui, DO4 and Santosh L. Saraf, MD5

1University of Illinois Chicago, Chicago
2University of Illinois Chicago, Chicago, IL
3Division of Hematology and Oncology, University of Illinois Chicago, Chicago, IL
4Hematology Oncology, University of Illinois, Burr Ridge, IL
5Department of Medicine, University of Illinois College of Medicine, Willowbrook, IL


Association of Neighborhood Crime with AML Molecular Subtypes and Survival

Michelle Nwachukwu, DO1, Garth Rauscher2, Ivy Abraham3, John G Quigley4, Judith Sayad5, Ami Dave6, Andrew Wilmington, MD7, Chen Zhang, MD, MS8, Anand Ashwin Patel, MD9, Andrew Palmer, BS10, Syed Shah, MBBS11, Hamed Youshanlouei12, Stephanie B. Tsai13, Mark DeBettencourt14, Gauri Shankar14, Ahmed Aleem, MD15, Nepheli Raptis, MA, BA16, Bukky Florence Tabiti, MD17, Peter Doukas, MD18, Madelyn Burkhart19, Maryam Zia, MD20, Amani Erra21 and Irum Khan, MD22

1University of Illinois Chicago, Chicago, IL
2University of Illinois Chicago School of Public Health, Chicago, IL
3UChicago Medicine, Flossmoor, IL
4Division of Hematology/Oncology, University of Illinois, Chicago, Chicago, IL
5University of Illinois Chicago, Chicago
6Levine Cancer Institute, Atrium Health, Charlotte
7Rush University, Chicago
8Rush University Medical Center, Chicago, IL
9Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
10University of Chicago Pritzker School of Medicine, Chicago, IL
11University of Chicago, Chicago, IL
12Section of Hematology/Oncology, The University of Chicago, Chicago, IL, Chicago
13Loyola University Medical Center, Chicago, IL
14Loyola University Medical Center, Maywood
15Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL
16Loyola University Stritch School of Medicine, Maywood, IL
17, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
18Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
19Wake Forest Baptist, Atrium Health, Winston-Salem
20Hematology-Oncology & Cellular Therapy (Division), SSM Health Saint Louis University Hospital, St. Louis, MO
21Division of Hematology and Oncology, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
22Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL


Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Andrew Palmer, BS1, Garth Rauscher2, Alexa Schoen3, Madelyn Burkart, MD4, Ashley Dunton5, Cherry Au6, Ami Dave7, Ahmad Nassar, MBBS8, Shaoshi Zhu9, Amani Erra10, Vinod Solipuram, MD11, Ivy Abraham12, Stephanie B. Tsai13, Maryam Zia, MD14, Melissa L. Larson15, Damiano Rondelli, MD16, Jessica K. Altman, MD17, Wendy Stock, MD18, Irum Khan, MD19, Olatoyosi Odenike, MD18 and Anand Ashwin Patel, MD18

1University of Chicago Pritzker School of Medicine, Chicago, IL
2University of Illinois Chicago School of Public Health, Chicago, IL
3Department of Medicine, Northwestern University, Chicago, IL
4Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
5Rush University, Chicago, IL
6Rush University, Chicago
7Division of Hematology, Oncology and Stem Cell Transplant, Rush University, Chicago
8University of Illinois Chicago, Chicago, IL
9University of Illinois College of Medicine, Chicago
10Division of Hematology and Oncology, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
11John H. Stroger Jr. Hospital of Cook County, Chicago
12UChicago Medicine, Flossmoor, IL
13Loyola University Medical Center, Chicago, IL
14Division of Hematology and Oncology, John H. Stroger Hospital of Cook County, Chicago, IL
15Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL
16Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
17Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL
18Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
19Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL


Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging

Sen Zhang, PhD1, Charles Ayemoba1, Anna M Di Staulo1, Ken Joves2, Eva Hw Leung2, Chandani M Patel1, Maria Maryanovich, PhD3, Konstantinos Chronis, PhD2 and Sandra Pinho, PhD1

1Department of Pharmacology & Regenerative Medicine, University of Illinois Chicago, Chicago, IL
2Department of Biochemistry & Molecular Genetics, University of Illinois Chicago, Chicago, IL
3Ruth L. and David S. Gottesman Institute for Stem Cell Biology and Regenerative Medicine, Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY


Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study

Natalie Wuliji, DO1,2, Ted Gooley, PhD3, Salene Jones, PhD, MA1, Aaron T. Gerds, MD, MS4, Bruno Medeiros, MD5, Paul J. Shami, MD6, John Galvin, MD, MPH7, Kehinde Adekola, MBBS, MS8, Selina Luger, MD, FRCPC9, Maria R. Baer, MD10, David A. Rizzieri, MD11, Tanya M. Wildes, MD, MSc12, Eunice S. Wang, MD13, Mikkael A. Sekeres, MD14, Sudipto Mukherjee, MD, PhD, MPH4, Julie C. Smith15, Mitchell A. Garrison, MD, MBA15, Kiarash Kojouri, MD, MPH16, Jacob S. Appelbaum, MD, PhD1,2, Mary-Elizabeth M. Percival, MD1,2, Brenda M. Sandmaier, MD2,17, Frederick R. Appelbaum, MD1,2 and Mohamed Sorror, MD, MSc1,2

1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
2Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA
3Fred Hutchinson Cancer Center, Seattle, WA
4Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
5Department of Medicine, Division of Hematology, Stanford University, Palo Alto, CA
6University of Utah Huntsman Cancer Institute, Salt Lake City, UT
7University of Illinois, University of Illinois Cancer Center, Chicago, IL
8Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
9Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
10University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD
11Novant Health Cancer Institute, Charlotte, NC
12University of Nebraska Medical Center, Omaha, NE
13Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
14Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
15Confluence Health, Wenatchee, WA
16Skagit Valley Hospital, Mount Vernon, WA
17Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA


Heavy Menstrual Bleeding in Adult Women with Sickle Cell Disease

Saahil Patel, Medical Student1, Fiona Busser, Medical Student1, Caitlin Lu, BS2, Jennifer Light, MD3 and Marwah Farooqui, DO4

1Midwestern University CCOM, Downers Grove, IL
2University of Illinois, Chicago, IL
3University of Illinois College of Medicine – Peoria, Peoria, IL
4Division of Hematology/Oncology, University of Illinois Chicago, Chicago, IL


First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Karen Sweiss, PharmD1, Jay R. Hydren, PhD2, Jorge Arturo Hurtado Martinez, MD2, Mason S. Barnes, B.S.2, Pritesh Patel, MD3, Douglas W. Sborov, MD, MS4, Jennifer M. Ahlstrom, BA2, Lisa Sharp, PhD, BSN, MA5 and Craig C. Hofmeister, MD6

1Department of Pharmacy Practice, University of Illinois Chicago, Hinsdale, IL
2HealthTree Foundation, Lehi, UT
3Division of Hematology/Oncology, University of Illinois Chicago, Chicago, IL
4University of Utah School of Medicine, Salt Lake City, UT
5University of Illinois Chicago, Chicago, IL
6Winship Cancer Institute of Emory University, Atlanta, GA


Has ABO Mismatch Rate Decreased in AML and ALL Transplant Recipients over the Years, a Trend Analysis Using CIBMTR Data

Ahsan Wahab, MD1, Karen Sweiss, PharmD2, Noah Birch, MD, PhD3 and Matias Sanchez, MD2

1University of Illinois Chicago, Chicago, IL
2Division of Hematology/Oncology, University of Illinois Cancer Center, Chicago, IL
3Division of Hematology & Oncology, University of Illinois Chicago, Chicago, IL


Hematopoietic Stem Cell Transplantation (HCST) Is Underutilized in Black Patients with Myeloid Neoplasms. Results from a Retrospective Study at Chicago’s Leading Minority-Serving Hospital

Ekrem Turk, MD1, Maha Elsebaie, MD2, Vaishali Deenadayalan, MD3, Khaldun Obeidat, MD4, Ahmad Nanaa, MD5, Maryam Zia, MD6 and Noah Birch, MD, PhD7

1John H Stroger Hospital Jr Hospital of Cook County, Chicago, IL
2Hematology and Oncology, University of Chicago, Chicago
3Roswell Park Comprehensive Cancer Center, Buffalo, NY
4Department of Medicine, University of Wisconsin, Madison, WI
5Hematolog and Oncology, University of Illinois Chicago, Chicago
6Hematology-Oncology & Cellular Therapy (Division), SSM Health Saint Louis University Hospital, St. Louis, MO
7Division of Hematology & Oncology, University of Illinois Chicago, Chicago, IL


Do Jehovah’s Witnesses with Sickle Cell Disease Avoid the Healthcare System?

Bukky Florence Tabiti, MD1 and Lewis L Hsu, MD, PhD2,3

1, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
2Sickle Cell Center / Pediatric Hematology-Oncology, University of Illinois Chicago, Chicago, IL
3University of Illinois, Chicago, IL


Association of Rh Mismatch with Primary Graft Failure and Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients with Acute Leukemia, a CIBMTR Analysis

Ahsan Wahab, MD1, Karen Sweiss, PharmD2 and Matias Sanchez, MD2

1University of Illinois Chicago, Chicago, IL
2Division of Hematology/Oncology, University of Illinois Cancer Center, Chicago, IL


The Impact of Structural Racism on Molecular Subtypes and Survival Outcomes in Acute Myeloid Leukemia Patients

Michelle Nwachukwu, DO

University of Illinois Chicago, Chicago, IL


A Pilot Trial Using Implementation Science to Improve Documentation and Disclosure of Sickle Cell Trait during Infancy

Corinna L. Schultz, MD, MSHP1,2, Kelsey Higgins3, Alison Taggi Pinto, M.Ed.3, Morgan Thomas, MGC, CGC4, Melanie L Pitone, MD5, Judith Feinson, MPH5, Amanda M. Lewis, MPH3, Jobayer Hossain, PhD6, Kim Smith-Whitley, MD7,8, Lewis L Hsu, MD, PhD9 and Melissa A. Alderfer, PhD1,3

1Department of Pediatrics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA
2Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children’s Health, Wilmington, DE
3Center for Healthcare Delivery Science, Nemours Children’s Health, Wilmington, DE
4Children’s Hospital of Philadelphia, Philadelphia, PA
5Center for Health Delivery Innovation, Nemours Children’s Health, Wilmington, DE
6Nemours Children’s Health, Wilmington, DE
7Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA
8Pfizer, Inc., New York, NY
9Sickle Cell Center / Pediatric Hematology-Oncology, University of Illinois Chicago, Chicago, IL


Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study

Andrew J. Cowan, MD1, Luuk Gras2, Hiroyuki Takamatsu, MD, PhD3,4, Linda Koster5, Laurien Baaij III6, Nada Hamad, MBBS, MSc, BSc7, Anita D’Souza, MD8, Noel Estrada-Merly, MS9, Parameswaran N. Hari, MD, MBBS10, Wael Saber, MD, MS11, Minako Iida, MD, PhD12, Shinichiro Okamoto13, Shohei Mizuno, MD, PhD14, Koji Kawamura, MD, PhD15, Yoshihisa Kodera, MD16, Bor-Sheng Ko, M.D. Ph.D.17, Christopher Liam, MRCP18, KIM Wah HO, MBBS, MRCP19, A Sim Goh, MD20, S Keat Tan21, Alaa M. Elhaddad, MD22, Ali Bazarbachi, MD, PhD23, Brig Qamar Un N Chaudhry, MBBS, FCPS24, Rozan Alfar, MBBS25, Mohamed Amine Bekadja26, Malek Benakli, MD27, Cristobal Augusto Frutos Ortiz, MD28, Eloisa Riva, MD, MEd29, Sebastian Galeano, MD30, Francisca Bass, MD31, Hira Mian, MD32, Arleigh McCurdy, MD33, Feng-Rong Wang, MD34, Meng Lv, MD, PhD35, Daniel Neumann36, Mickey Boon Chai Koh, MD, PhD37, John Snowden, MD38, Stefan Schonland39, Donal P McLornan, MD, PhD40, Patrick John Hayden, MD41, Rafael De La Camara, MD42, Raffaella Greco, MD43, Fabio Ciceri, MD44, Mette D. Hazenberg, MD, PhD45, Anna Sureda Balari, MD, PhD46, Damiano Rondelli, MD47, Hildegard T. Greinix, MD48, Mahmoud Aljurf49, Yoshiko Atsuta50, Dietger W. Niederwieser, MD51 and Laurent Garderet52

1Fred Hutchinson Cancer Center, Seattle, WA
2EBMT, Leiden, Netherlands
3Department of Hematology, Kanazawa University, Kanazawa, Japan
4Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
5EBMT Leiden Study Unit, Leiden, Netherlands
6EBMT Leiden Study Unit, Leiden, the Netherlands;, Leiden, Netherlands
7St Vincent’s Hospital, Sydney, NSW, Australia
8Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
9BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
10The Medical College of Wisconsin, Brookfield, WI
11Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
12Aichi Medical University School of Medicine, Nagakute-cho, Aichi, JPN
13Keio University School of Medicine, Tokyo, JPN
14Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan
15Division of Hematology and Clinical Laboratory Medicine, Tottori University Hospital, Yonago, Japan
16Aichi Medical University, Nagakute, AIC, JPN
17Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
18Hospital Sultanah Aminah, Johor Bahru, Malaysia
19Hospital Ampang, Ampang, Malaysia
20Penang General Hospital, Penang, Malaysia
21Hospital Pulau Pinang, Pulau Pinang, Malaysia
22Children Cancer Hospital Egypt – 57357, Cairo, Egypt
23American University of Beirut Dept. of Medicine, Beirut, Lebanon
24Pathwel center of Hematology and BMT, Rawalpindi, PAK
25Princess Margaret Hospital, Toronto, ON, CAN
26EHU, Oran, Algeria
27Pierre and Marie Curie Center, Algiers, Algeria
28Hospital Central Del Instituto De Prevision Social, Asuncion, Paraguay
29Hematology, Hospital de Clinicas, Montevideo, Uruguay
30Bone marrow transplant unit, British Hospital, Montevideo, Montevideo, Uruguay
31Intensive Hematology Unit, Hospital Del Salvador, Santiago, Chile
32McMaster University, Hamilton, ON, Canada
33The Ottawa Hospital, Ottawa, ON, Canada
34Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, CHN
35Peking University People’s Hospital, Beijing, China
36Leipzig University, Leipzig, DEU
37St George’s University Hospitals, London, United Kingdom
38Sheffield Blood & Marrow Transplant and Cellular Therapy Programme, Sheffield, United Kingdom
39Medical Department V, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany
40Department of Haematology, University College London Hospitals NHS Trust, London, ENG, United Kingdom
41Department of Haematology, Trinity College Dublin, St. James’s Hospital, Dublin, Ireland
42Hospital Universitario de la Princesa, Madrid, Spain
43Unit of Hematology and Stem Cell Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy
44Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. San Raffaele Scientific Institute, Milan, Italy
45Department of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands
46Hematology Department, Institut Català d’Oncologia – Hospitalet, IDIBELL, University of Barcelona, Hospitalet de Llobregat, Spain
47Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
48Division of Hematology, Medical University of Graz, Graz, Austria
49Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
50The Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan
51Universitaetsklinikum Leipzig Aor, Leipzig, Germany
52Hematology, Pitie-Salpetriere Hospital, Greater Paris University Hospitals (AP-HP), Paris, France


Novel MET Inhibitors Provide a Therapeutic Opportunity for AML By Overcoming the Protective Action of the Bone Marrow Niche

Maura Lima Pereira Bueno1, Charles Ayemoba2, Anna M Di Staulo2, Sen Zhang, PhD2, Fernanda Soares Niemann, MSc1, Nádia Ghinelli Amôr, PhD1, Irene Santos, MSc1, Adriana da Silva Santos Duarte, PhD1, Audrey Bastos1, Sara Teresinha Olalla Saad, MD PhD1, Sandra Pinho, PhD2 and Fernanda Marconi Roversi, PhD1,3

1Hematology and Transfusion Medicine Center, State University of Campinas (UNICAMP), Campinas, Brazil
2Department of Pharmacology & Regenerative Medicine, University of Illinois Chicago, Chicago, IL
3Department of Surgery, Emory University, Atlanta


PIM447, a Pan-PIM Kinase Inhibitor, in Combination with Venetoclax Exerts a Potent Anti-Tumor Activity in the Bone Marrow Niche

Fernanda Marconi Roversi, PhD1,2, Maura Lima Pereira Bueno2, Samara de Sousa Mariano3, Fernanda Soares Niemann, MSc2, Adriana da Silva Santos Duarte, PhD2, Audrey Bastos2, Nádia Ghinelli Amôr, PhD2, Irene Santos, MSc2, Jose Andres Yunes4, Sandra Pinho, PhD5 and Sara Teresinha Olalla Saad, MD PhD2

1Department of Surgery, Emory University (currently), Atlanta, GA
2Hematology and Transfusion Medicine Center, State University of Campinas – UNICAMP, Campinas, Brazil
3Centro Infantil Boldrini, Campinas, Brazil
4Boldrini Research Center, Campinas, Sao Paulo, Brazil
5Department of Pharmacology & Regenerative Medicine, University of Illinois Chicago, Chicago, IL


Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Meral Beksac, MD1, Simona Iacobelli2, Luuk Gras3, Linda Koster4, Laurien Baaij4, Nada Hamad, MBBS, MSc, BSc5, Anita D’Souza, MD6, Noel Estrada-Merly, MS7, Parameswaran N. Hari, MD, MBBS8, Andrew J. Cowan, MD9, Wael Saber, MD, MS10, Minako Iida, MD, PhD11, Shinichiro Okamoto12, Hiroyuki Takamatsu, MD, PhD13, Shohei Mizuno, MD, PhD14, Koji Kawamura, MD, PhD15, Yoshihisa Kodera, MD16, Bor-Sheng Ko, M.D. Ph.D.17, Christopher Liam, MRCP18, KIM Wah HO, MBBS, MRCP19, A Sim Goh, MD20, S Keat Tan21, Alaa M. Elhaddad, MD22, Ali Bazarbachi, MD, PhD23, Qamar-un-Nisa Chaudhry24, Rozan Alfar25, Mohamed Amine Bekadja26, Malek Benakli, MD27, Cristobal Augusto Frutos Ortiz, MD28, Eloisa Riva, MD, MEd29, Sebastian Galeano, MD30, Francisca Bass, MD31, Hira Mian, MD32, Arleigh McCurdy, MD33, Feng Rong Wang34, Meng Lv, MD, PhD35, Daniel Neumann36, Mickey Boon Chai Koh, MD, PhD37, John Snowden, MD38, Stefan O. Schönland, MD39, Donal P McLornan, MD, PhD40, Patrick J Hayden, MD, PhD41, Damiano Rondelli, MD42, Hildegard Greinix43, Mahmoud Aljurf44, Yoshiko Atsuta45, Ana Sureda Balari46, Dietger W. Niederwieser, MD47 and Laurent Garderet, MD, PhD48

1Hematology, Istinye University Ankara Liv Hospital, Ankara, Turkey
2Centro Di Biostatistica E Bioinformatica Università Tor Vergata, Rome, ITA
3EBMT, Leiden, Netherlands
4EBMT Leiden Study Unit, Leiden, Netherlands
5School of Clinical Medicine, Faculty of Medicine and Health, The University of New South Wales, Sydney, NSW, Australia
6Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
7BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
8The Medical College of Wisconsin, Brookfield, WI
9University of Washington, Seattle, WA
10Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
11Aichi Medical University School of Medicine, Nagakute-cho, Aichi, JPN
12Keio University School of Medicine, Tokyo, JPN
13Department of Hematology, Kanazawa University, Kanazawa, Japan
14Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi, Japan
15Division of Hematology and Clinical Laboratory Medicine, Tottori University Hospital, Yonago, Japan
16Aichi Medical University, Nagakute, AIC, JPN
17Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
18Hospital Sultanah Aminah, Johor Bahru, Malaysia
19Hospital Ampang, Ampang, Malaysia
20Penang General Hospital, Penang, Malaysia
21Hospital Pulau Pinang, Pulau Pinang, Malaysia
22Children Cancer Hospital Egypt – 57357, Cairo, Egypt
23American University of Beirut Dept. of Medicine, Beirut, Lebanon
24AFBMTC/NIBMT, Rawalpindi, Pakistan
25King Hussein Cancer Center, Amman, Jordan
26EHU, Oran, Algeria
27Pierre and Marie Curie Center, Algiers, Algeria
2825Hospital Central Del Instituto De Prevision Social, Asuncion, Paraguay
29Hematology, Hospital de Clinicas, Montevideo, Uruguay
30Bone marrow transplant unit, British Hospital, Montevideo, Montevideo, Uruguay
31Intensive Hematology Unit, Hospital Del Salvador, Santiago, Chile
32McMaster University, Hamilton, ON, Canada
33The Ottawa Hospital, Ottawa, ON, Canada
34Peking University, Peking, China
35Peking University People’s Hospital, Beijing, China
36IMISE, university of Leipzig, Leipzig, Germany
37St George’s University Hospitals, London, United Kingdom
38BSBMTCT, Department of Haematology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom
39Medical Department V, Amyloidosis Center,, University of Heidelberg, Heidelberg, Germany
40Department of Haematology, University College London Hospitals NHS Trust, London, ENG, United Kingdom
41Trinity College Dublin, St. James’s Hospital, Dublin, IRL
42Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
43Medical University of Graz, Graz, Austria
44Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
4541Japanese Data Center for Hematopoietic Cell Transplantation, Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan
46Instituto Catalán de Oncología – Hospital Duran i Reynals, Barcelona, Spain
47Universitaetsklinikum Leipzig Aor, Leipzig, Germany
48Department of Hematology, Hopital Saint Antoine, Paris, FRA


A Novel Oral Prodrug AN233 Induces Fetal Hemoglobin Expression in Sickle Cell Disease Mice and Baboons

Chithra D. Palani, PhD1,2, Abraham Nudelman, PhD3, Ada W. Rephaeli, PhD4, Donald E. Lavelle, PhD5, Manickam Alagar, PhD6, Nikhil Patel, MD7, Zhi Wenbo, PhD8 and Betty S. Pace, MD2,9

1Department of Pediatrics, Augusta University, Augusta, GA
2Georgia Cancer Center, Augusta University, Augusta, GA
3Chemistry Department, Bar Ilan University, Ramat Gan, Israel
4Felsenstein Medical Research Center, Petach Tikva, Israel
5Department of Medicine, University of Illinois Chicago, Chicago, IL
6Stem Cell Processing Lab, Transfusion Services, Wellstar MCG Health, Augusta, GA
7Department of Pathology and Laboratory Medicine, Medical College of Georgia at Augusta University, Augusta, GA
8Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA
9Division of Hematology/Oncology, Augusta University, Augusta, GA


IFN-I Promotes T Cell-Independent Immunity and RBC Autoantibodies Via Modulation of B-1 Cell Subsets in Murine SCD

Shan Su, PhD1, Weili Bao, MS1*, Yunfeng Liu, PhD1, Patricia Shi, MD2, Deepa Manwani, MD3, Irina Murakhovskaya, MD4, Sally Campbell Lee, MD5, Cheryl Lobo, PhD6, Avital Mendelson, PhD7, Xiuli An, MD, PhD8, Hui Zhong, PhD9, Woelsung Yi, PhD1* and Karina Yazdanbakhsh, PhD1

1Laboratory of Complement Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY
2New York Blood Center, New York, NY
3Department of Pediatric Hematology-Oncology, Albert Einstein College of Medicine, Bronx, NY
4Division of Hematology, Department of Medicine, Montefiore Medical Center, Brooklyn, NY
5Department of Pathology, University of Illinois Chicago, Chicago, IL
6Laboratory of Blood-Borne Parasites, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY
7Laboratory of Stem Cell Biology and Engineering, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY
8Laboratory of Membrane Biology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY
9Laboratory of Immune Regulation, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY


Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Ariela Noy, MD1, Stefan K. Barta, MD2, Deukwoo Kwon, PhD3*, Robert Baiocchi, MD, PhD4, Juan Carlos Ramos, MD5, Paul Rubinstein, MD6, Amy Chadburn, MD7 and Richard F. Ambinder, MD8,9

1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Abramson Cancer Center, The Fox Chase Cancer Center Foundation, Philadelphia, PA
3Icahn School of Medicine at Mount Sinai, New York, NY
4Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH
5Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
6Division of Hematology/Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL
7Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
8Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
9Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD


Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia

Dhabya Majid, BS1, Zhe WANG, MD1*, Bin Yuan, PhD2, Mhd Yousuf Yassouf, PhD3, Amanda Schalk, PhD4, Basant T. Gamal, MS5, Qi Zhang Tatarata, MD, PhD1, Jessica Lynn Root, MS6, Araceli Isabella Garza1, Annie Hoai Nguyen7, Sammy Ferri-Borgogno, PhD5, Patrick K. Reville, MD, MPH1, Arnon Lavie, PhD4 and Hussein A. Abbas, MD, PhD1,8

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2The University of Texas at MD Anderson Cancer center, Houston, TX
3Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
4University of Illinois, Chicago, IL
5University of Texas MD Anderson Cancer Center, Houston
6Department of Leukemia, The University of Texas MD Anderson Cancer center, Houston, TX
7Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston
8Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX


Mechanics of Spectrin As a Stiff Polymer

Zhangli Peng, PhD1, Timothy Leong1, Nima Mostafazadeh1 and Qiang Zhu, PhD2

1Department of Biomedical Engineering, University of Illinois Chicago, Chicago, IL
2University of California San Diego, La Jolla, CA


A Novel Oral Prodrug AN233 Induces Fetal Hemoglobin Expression in Sickle Cell Disease Mice and Baboons

Chithra D. Palani, PhD1,2, Abraham Nudelman, PhD3, Ada W. Rephaeli, PhD4, Donald E. Lavelle, PhD5, Manickam Alagar, PhD6, Nikhil Patel, MD7, Zhi Wenbo, PhD8 and Betty S. Pace, MD2,9

1Department of Pediatrics, Augusta University, Augusta, GA
2Georgia Cancer Center, Augusta University, Augusta, GA
3Chemistry Department, Bar Ilan University, Ramat Gan, Israel
4Felsenstein Medical Research Center, Petach Tikva, Israel
5Department of Medicine, University of Illinois Chicago, Chicago, IL
6Stem Cell Processing Lab, Transfusion Services, Wellstar MCG Health, Augusta, GA
7Department of Pathology and Laboratory Medicine, Medical College of Georgia at Augusta University, Augusta, GA
8Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA
9Division of Hematology/Oncology, Augusta University, Augusta, GA


Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Haydar Frangoul, MD1, Franco Locatelli, MD2, Akshay Sharma, MBBS3, Monica Bhatia, MD4, Markus Y Mapara, MD5, Robert I. Liem, MD6, Donna Wall, MD7, Lyndsay Molinari, MD8, Laurence Dedeken, MD9, Kevin H.M. Kuo, MD, MSc, FRCPC10, Paul Telfer, MD, FRCP11, Ami J. Shah, MD12, Marina Cavazzana, MD, PhD13, Selim Corbacioglu, MD, PhD14, Michael J. Eckrich15, Damiano Rondelli, MD16, Roland Meisel, MD17, Stephan Lobitz, MD, MSc18, Mariane De Montalembert, MD, PhD13, Martin H. Steinberg, MD19, Mark C. Walters, MD20, Laura Bower, MD21, Suzan Imren, MD21, Tina Liu, PhD21, Weiyu Zhou, PhD21, William Hobbs, MD, PhD21 and Stephan A. Grupp, MD, PhD22

1Sarah Cannon Research Institute at the Children’s Hospital at TriStar Centennial, Nashville, TN
2IRCCS, Ospedale Pediatrico Bambino Gesù Rome, Catholic University of the Sacred Heart, Rome, Italy
3Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN
4Department of Pediatrics, Columbia University Irving Medical Center, New York Presbyterian-Morgan Stanley Children’s Hospital, New York, NY
5Department of Medicine, Division of Hematology & Oncology, Columbia University, New York
6Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
7The Hospital for Sick Children/University of Toronto, Toronto, Canada
8Sarah Cannon Pediatric Transplant and Cellular Therapy Program at Methodist Children’s Hospital, San Antonio, TX
9Hôpital Universitaire des Enfants Reine Fabiola, Brussels, BEL
10Division of Hematology, University of Toronto, Toronto, ON, Canada
11Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
12Stanford University, Palo Alto, CA
13Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University of Paris, Paris, France
14University of Regensburg, Regensburg, Germany
15Atrium Health in Charlotte, Charlotte, NC
16Division of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL
17Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
18Pädiatrische Hämatologie und Onkologie, Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany
19Boston University Chobanian & Avedisian School of Medicine, Boston, MA
20UCSF Benioff Children’s Hospital Oakland, Oakland, CA
21Vertex Pharmaceuticals Incorporated, Boston, MA
22Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA


Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia Is Associated with Overall Survival

Haley Hultquist1,2, Alyssa Rodriguez, MSc1,3, My H. Vu, MS4, Alexandra E. Kovach, MD5,6 and Paul S. Gaynon, MD1,5

1Hematology/Oncology, Children’s Hospital Los Angeles, Los Angeles, CA
2University of Illinois College of Medicine, Chicago, IL
3University of Minnesota Medical School, Minneapolis, MN
4Biostatistics, Children’s Hospital Los Angeles, Los Angeles, CA
5Keck School of Medicine of University of Southern California, Los Angeles, CA
6Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA


Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Ariela Noy, MD1, Stefan K. Barta, MD2, Deukwoo Kwon, PhD3, Robert Baiocchi, MD, PhD4, Juan Carlos Ramos, MD5, Paul Rubinstein, MD6, Amy Chadburn, MD7 and Richard F. Ambinder, MD8,9

1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
2Abramson Cancer Center, The Fox Chase Cancer Center Foundation, Philadelphia, PA
3Icahn School of Medicine at Mount Sinai, New York, NY
4Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH
5Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
6Division of Hematology/Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL
7Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
8Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD
9Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD


Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Matthew Hamby, BSc1, Brian Egleston, PhD2, Zachary AK Frosch, MD, MSHP3, Raphael E. Steiner, MD4, Ariela Noy, MD4, Veronica Carvajal, BS5, Seda S. Tolu, MD6, Gaston Jean-Louis, MD7, Jennifer E. Amengual, MD8, Romil Patel, MD9, Sairah Ahmed, MD9,10,11, Timothy Voorhees, MD, MSc12, Robert Baiocchi, MD, PhD13, Andres Ramirez-Gamero, MD14, Jorge J. Castillo, MD14,15, Emily Hamburger, MD16, Christopher Dittus, DO16, Imran A. Nizamuddin, MD17, Neha Mehta-Shah, MD18,19, Nyein Nyein Thaw Dar, MBBS, MSc20, Jose Sandoval-Sus, MD21, Alexandra E. Rojek, MD22, Peter A. Riedell, MD22, Vinod Solipuram, MD23, Paul G. Rubinstein, MD24, Anthony Ariotti25, Gita Suneja, MD, MS25, Alexander Vartanov, MD26, Charles Milrod, MD27, Adam J. Olszewski, MD28, Gordon Smilnak, MD29, Emily Ayers, MD29, Sahaj Desai, MD30, Joanna M. Rhodes, MD30, Gabriella Magarelli, MSN, ACNP-BC, AOCNP31, Tatyana Feldman, MD32, Meredith Pellon33, David M. Aboulafia, MD34, William Bae, MD35, Carlos Galvez, MD35, Vineel Bhatlapenumarthi, MD36, Mehdi Hamadani, MD37 and Stefan K. Barta, MD38,39

1University of Pennsylvania, Lancaster, PA
2Fox Chase Cancer Center, Philadelphia, PA
3Department of Hematology/Oncology; Cancer Prevention and Control Research Program, Fox Chase Cancer Center, Philadelphia, PA
4Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia
6Division of Hematology & Oncology, Columbia University Irving Medical Center, New York City, NY
7Columbia University, New York, NY
8Division of Hematology & Oncology, Columbia University Irving Medical Center, New York
9Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
10Department of Lymphoma/Myeloma and Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX
11MD Anderson Cancer Center, Houston, TX
12Division of Hematology, The Ohio State University, Columbus, OH
13James Comprehensive Cancer Center, The Ohio State University, Columbus, OH
14Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, MA
15Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
16Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
17Division of Oncology, Washington University School of Medicine, St. Louis, MO
18Siteman Cancer Center, Washington University in St. Louis, St Louis, MO
19Siteman Cancer Center, Washington University School of Medicine, Olivette, MO
20Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, FL
21Department of Malignant Hematology and Cellular Therapy, Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, FL
22Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
23John H. Stroger Jr. Hospital of Cook County, Chicago
24John Stroger Cook County Hospital, Chicago, IL
25Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
26Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA
27Department of Hematology/Oncology, Brown University, Providence, RI
28Brown University, Providence, RI
29University of Virginia, Charlottesville, VA
30Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
31John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
32Hackensack Meridian Health Hackensack University Medical Center, NY, NY
33Virginia Mason Medical Center, Seattle, WA
34Virginia Mason Clinic, Seattle, WA
35Division of Hematology/Oncology, University of Illinois Chicago, Chicago, IL
36Department of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI
37Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
38Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA
39Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA


Curative Therapies in Sickle Cell Disease: Which Patient, What Modality, and When to Refer

Santosh L. Saraf, MD

University of Illinois Chicago, Chicago, IL


Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells

Qiong Wu, PhD1, Chunjie Yu, PhD1, Fang Yu, PhD1, Yiran Guo, PhD2, Yue Sheng, PhD3, Liping Li, MD4, Yafang Li, PhD1, Yutao Zhang3, Chao Hu, MD5, Jue Wang, PhD1, Tong-Chuan He, PhD6, Yong Huang, PhD7, Hongyu Ni, MD8, Zhigang Hou, PhD9, Wenshu Wu, PhD5, Greg G Wang, PhD10, Jianxin Lyu, PhD11 and Zhijian Qian1

1Division of Hematology/Oncology, Department of Medicine and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL
2Department of Pharmacology and Cancer Biology, Duke University, Durham, NC
3Division of Hematology/Oncology, Department of Medicine and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville
4Department of Pathology at Geisinger Medical Center, Danville
5University of Illinois Chicago, Chicago
6University of Chicago, Chicago
7University of Virginia, Charlottesville
8Cedars Sinai Medical Center, Los Angeles, CA
9Department of Biostatistics, University of Florida, Gainesville
10Department of Pharmacology and Cancer Biology, Duke University, Durham
11People’s Hospital of Hangzhou Medical College, Hangzhou, CHN

Translate »